https://scholars.lib.ntu.edu.tw/handle/123456789/462201
標題: | BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer | 作者: | KUO-HSING CHEN Lin Y.-L. JAU-YU LIAU JIA-HUEI TSAI LI-HUI TSENG LIANG-IN LIN JIN-TUNG LIANG BEEN-REN LIN JI-SHIANG HUNG YIH-LEONG CHANG KUN-HUEI YEH ANN-LII CHENG |
公開日期: | 2016 | 出版社: | Humana Press Inc. | 卷: | 33 | 期: | 5 | 來源出版物: | Medical Oncology | 摘要: | The prognostic implication of BRAF mutant colorectal cancer remains paradoxical. Records of BRAF mutant and wild-type colorectal cancer patients at all stages were reviewed. Clinicopathologic features, including microsatellite instability, CpG islands methylator phenotype, and overall survival, of these patients were analyzed. Between 2005 and 2013, 428 colorectal cancer patients were enrolled in this study. The overall survival between BRAF mutant and wild-type patients with early-stage (stages I and II) colorectal cancer differed nonsignificantly (P?=?0.99). By contrast, in late-stage (stages III and IV) patients, the median overall survival of BRAF mutant patients (N?=?25) was significantly poorer than that of BRAF wild-type (N?=?207) patients (BRAF mutant: 21.3?months (95?% confidence interval [CI] 7.1–35.5); BRAF wild-type: 53.5?months (95?% CI 37.5–69.5), P?0.0001). In early-stage patients, we found that BRAF mutation was significantly associated with CpG island methylator phenotype-positive (P?0.001), and microsatellite instability-high status (P?=?0.0013). Conversely, in late-stage patients, BRAF mutation was significantly associated with CpG island methylator phenotype-positive (P?=?0.0015) and the right-side colon (P?=?0.014). BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer. ? 2016, Springer Science+Business Media New York. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84962439814&doi=10.1007%2fs12032-016-0756-6&partnerID=40&md5=27e2efae3b2810f289d2118933016c42 https://scholars.lib.ntu.edu.tw/handle/123456789/462201 |
ISSN: | 1357-0560 | DOI: | 10.1007/s12032-016-0756-6 | SDG/關鍵字: | B Raf kinase; bevacizumab; cetuximab; fluorouracil; folinic acid; irinotecan; oxaliplatin; B Raf kinase; BRAF protein, human; adjuvant therapy; adult; Article; cancer adjuvant therapy; cancer combination chemotherapy; cancer patient; cancer prognosis; cancer staging; cancer surgery; cancer survival; chemoembolization; clinical feature; colorectal cancer; controlled study; CpG island; female; genetic association; human; local therapy; major clinical study; male; medical record review; metastasis resection; methylator phenotype; microsatellite instability; monotherapy; multimodality cancer therapy; mutant; mutational analysis; overall survival; phenotype; priority journal; radiofrequency ablation; retrospective study; systemic therapy; tumor ablation; wild type; aged; colorectal tumor; DNA methylation; genetics; Kaplan Meier method; middle aged; mortality; multivariate analysis; mutation; pathology; prognosis; Aged; Colorectal Neoplasms; CpG Islands; DNA Methylation; Female; Humans; Kaplan-Meier Estimate; Male; Microsatellite Instability; Middle Aged; Multivariate Analysis; Mutation; Prognosis; Proto-Oncogene Proteins B-raf |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。